What is the price-to-earnings ratio of Ergomed?
The price-earnings ratio of Ergomed is currently 25.4.
Ergomed P/E 2024
Ergomed P/E
25.4
Ticker
ERGO.L
ISIN
GB00BN7ZCY67
WKN
A117XM
As of Sep 13, 2024, Ergomed's P/E ratio was 25.4, a 17.27% change from the 21.66 P/E ratio recorded in the previous year.
The Ergomed P/E history
Ergomed Aktienanalyse
What does Ergomed do?
Ergomed PLC is a company specialized in clinical research, based in the UK since 1997. It specializes in supporting biotech and pharmaceutical companies in conducting clinical phase studies and post-marketing surveillance. Ergomed is listed on the London Stock Exchange and has offices in Europe and the USA. The company was originally founded as Ergomed Clinical Research Limited by physician Miroslav Reljanovic, who recognized the lack of resources for small biotech companies to conduct their own clinical studies. Ergomed offers a range of services tailored to the needs of biotech and pharmaceutical companies, including clinical research services, medical information and pharmacovigilance services, and regulatory affairs. It also provides venture capital investments for selected biotech companies. Ergomed offers comprehensive clinical research services, including study planning, trial management, and study monitoring. It also has expertise in data management and statistics to ensure accurate results. The company provides medical information to inform patients and healthcare professionals and offers support for drug monitoring during and after approval. Ergomed also supports companies in submitting regulatory applications and addressing regulatory questions. It has extensive experience working with national, European, and global regulatory authorities to ensure drug approval and compliance. Ergomed does not offer its own products but provides services to biotech and pharmaceutical companies. It collaborates with various companies to conduct clinical trials and develop drugs. In conclusion, Ergomed is a specialized company in clinical research that offers a wide range of services to biotech and pharmaceutical companies. It specializes in supporting them in conducting clinical phase studies and post-marketing surveillance. Ergomed has extensive experience working with regulatory authorities at national, European, and global levels to ensure drug approval and compliance. Ergomed ist eines der beliebtesten Unternehmen auf Eulerpool.com.P/E Details
Deciphering Ergomed's P/E Ratio
The Price to Earnings (P/E) Ratio of Ergomed is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.
Year-to-Year Comparison
Assessing Ergomed's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.
Impact on Investments
The P/E ratio of Ergomed is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.
Interpreting P/E Ratio Fluctuations
Fluctuations in Ergomed’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.
Frequently Asked Questions about Ergomed stock
How has the price-earnings ratio of Ergomed changed compared to last year?
The price-to-earnings ratio of Ergomed has increased by 17.27% increased compared to last year.
What consequences does a high price-earnings ratio have for investors?
A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.
What does a low price-earnings ratio mean?
A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.
Is the price-earnings ratio of Ergomed high compared to other companies?
Yes, the price-to-earnings ratio of Ergomed is high compared to other companies.
How does an increase in the price-earnings ratio of Ergomed affect the company?
An increase in the price-earnings ratio of Ergomed would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.
How does a reduction in the price-to-earnings ratio of Ergomed affect the company?
A decrease in the price-earnings ratio of Ergomed would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.
What are some factors that influence the price-earnings ratio of Ergomed?
Some factors that influence the price-earnings ratio of Ergomed are the company's growth, financial position, industry development, and the overall economic situation.
How much dividend does Ergomed pay?
Over the past 12 months, Ergomed paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Ergomed is expected to pay a dividend of 0 GBP.
What is the dividend yield of Ergomed?
The current dividend yield of Ergomed is .
When does Ergomed pay dividends?
Ergomed pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Ergomed?
Ergomed paid dividends every year for the past 0 years.
What is the dividend of Ergomed?
For the upcoming 12 months, dividends amounting to 0 GBP are expected. This corresponds to a dividend yield of 0 %.
In which sector is Ergomed located?
Ergomed is assigned to the 'Health' sector.
Wann musste ich die Aktien von Ergomed kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Ergomed from 9/13/2024 amounting to 0 GBP, you needed to have the stock in your portfolio before the ex-date on 9/13/2024.
When did Ergomed pay the last dividend?
The last dividend was paid out on 9/13/2024.
What was the dividend of Ergomed in the year 2023?
In the year 2023, Ergomed distributed 0 GBP as dividends.
In which currency does Ergomed pay out the dividend?
The dividends of Ergomed are distributed in GBP.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Ergomed stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von Ergomed
Our stock analysis for Ergomed Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Ergomed Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
